Hormone optimization spans TRT for hypogonadal men and menopausal hormone therapy for women. TRT has strong evidence for sexual function, lean mass, bone density and quality of life, with cardiovascular effects still contested. For women, the WHI's 2002 cancer scare has been substantially revised: starting therapy before 60 or within 10 years of menopause appears safe and possibly cardioprotective, with vasomotor relief and bone preservation the proven benefits, while transdermal estrogen and micronized progesterone carry lower clotting and breast-cancer risk than older oral and synthetic forms.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Is TRT safe and effective?
For men with symptoms plus low levels, the evidence is strong for libido, erectile function, lean mass, bone density and quality of life. Cardiovascular effects are genuinely mixed, so monitoring of hematocrit, estradiol, PSA and lipids is required.136
Does HRT cause breast cancer?
The WHI found increased risk with estrogen plus the synthetic progestin MPA. Estrogen alone in women without a uterus was neutral or slightly protective, and cohort data show micronized progesterone carries lower risk than synthetic progestins.789
Does HRT timing change its risk profile?
Timing matters. Starting before 60 or within 10 years of menopause shows a favorable profile, while starting later raises cardiovascular and dementia risk. The strongest indications remain hot flashes, genitourinary symptoms and bone protection.1011
Core thesis: Hormonal decline is one of the most treatable causes of age-related deterioration. Testosterone, estrogen, thyroid, DHEA, and growth hormone all decline with age — but conventional medicine considers this "normal" and rarely treats it. Thoughtful hormone optimization, guided by symptoms and labs, can dramatically improve quality of life, body composition, cognitive function, and potentially longevity.
02The Endocrine System and Aging
The Hormone Decline
| Hormone | Peak Age | Decline Pattern | Clinical Impact |
|---|---|---|---|
| Testosterone (men) | ~20 | ~1-2%/year after 30 | Muscle loss, fatigue, libido decline, mood changes |
| Estrogen (women) | ~25-30 | Sharp decline at menopause (~50) | Bone loss, hot flashes, cardiovascular risk, cognitive decline |
| DHEA | ~25 | Progressive decline | Reduced vitality, immune function |
| Growth Hormone/IGF-1 | ~20 | ~14%/decade after 30 | Body composition, recovery, skin |
| Thyroid (T3) | Variable | Gradual decline | Metabolism, energy, mood |
| Melatonin | ~10 | Progressive decline | Sleep quality, circadian rhythm |
| Pregnenolone | ~30 | Significant decline | "Mother hormone," neurosteroid, memory |
Swipe table →
The "Normal Range" Problem
- Lab reference ranges represent the 2.5th-97.5th percentile of the testing population
- This includes sick, elderly, and medicated individuals
- A 50-year-old man with "normal" testosterone of 350 ng/dL may be profoundly symptomatic
- Optimal ≠ normal. Many clinicians target the upper half or upper third of the reference range
03Testosterone Optimization (Men)
When to Consider TRT
- Symptoms + labs: Both required for diagnosis
- Symptoms: Low libido, erectile dysfunction, fatigue, depression, reduced muscle mass, increased body fat, brain fog, reduced motivation
- Lab thresholds (controversial): Total testosterone < 400 ng/dL with symptoms; free testosterone < 15 pg/mL
Benefits of TRT (Evidence)
| Outcome | Evidence Level | Key Findings |
|---|---|---|
| Sexual function | Strong | Improved libido, erectile function in hypogonadal men (PMID 39248210) |
| Body composition | Strong | Increased lean mass, decreased fat mass |
| Bone density | Strong | Increased BMD, reduced fracture risk |
| Mood/depression | Moderate | Improvement in hypogonadal men |
| Cardiovascular | Contested | Some studies show benefit, others show risk — likely depends on baseline, dosing, hematocrit management |
| Cognitive function | Emerging | Improvement in spatial and verbal memory |
| Quality of life | Strong | Consistent improvement in validated QoL measures |
Swipe table →
TRT Administration
| Method | Advantages | Disadvantages |
|---|---|---|
| Testosterone cypionate/enanthate (injections) | Flexible dosing, stable levels, low cost | Peaks and troughs, injection required |
| Topical gels | Non-invasive, daily steady state | Transfer risk to partners, skin irritation, variable absorption |
| Pellets | Long-acting (3-6 months), consistent | Minor procedure, cannot easily reverse |
| Buccal/sublingual | Rapid absorption | Multiple daily doses |
| Nasal gel (Natesto) | Minimal transfer risk, preserves fertility | Multiple daily doses, lower levels |
Swipe table →
Monitoring on TRT
- Every 3-6 months initially: Total + free testosterone, estradiol, CBC (hematocrit), PSA, lipids
- Annually: DEXA scan, cardiovascular assessment
- Target ranges: Total T 500-1000 ng/dL, free T 20-30 pg/mL, hematocrit < 54%, estradiol 20-40 pg/mL
Managing Side Effects
- Elevated hematocrit: Regular blood donation or phlebotomy; lower dose
- Elevated estradiol: Manage with dose adjustment first; aromatase inhibitors only if necessary
- Acne/skin: Usually dose-dependent
- Fertility preservation: hCG + FSH if fertility desired
04Perimenopause and Menopausal Hormone Therapy (Women)
Terminology and Staging
| Stage | Definition | Hormonal Signature | Symptom Profile |
|---|---|---|---|
| Reproductive | Regular cycles, fertility | Normal estradiol/progesterone | None |
| Perimenopause (menopause transition) | ~2-8 years before final period; cycle irregularity | Erratic estradiol spikes (often 2-3× normal) followed by drops; anovulatory cycles with low progesterone | VMS begin, sleep disruption, mood lability, cycle changes (PMID 40720963, AMY Study, Lancet Diabetes Endocrinol 2025) |
| Menopause | 12 months amenorrhea (median age ~50-51) | Permanent ovarian failure | VMS peak |
| Postmenopause | Years after final period | Persistently low estradiol + low progesterone | VMS decline; urogenital atrophy + bone loss + cardiometabolic shift accelerate |
Swipe table →
Key clinical point: Perimenopausal estradiol is often high (ovarian compensation), then crashes. A single "estradiol is high, no treatment needed" reading misses the volatility. Clinical decisions should track symptoms + cycle pattern over time, not single labs.
The Women's Health Initiative (WHI) — What Actually Happened
The WHI (2002) was two RCTs in 27,347 postmenopausal women (mean age 63) testing oral conjugated equine estrogens (CEE, Premarin) ± medroxyprogesterone acetate (MPA, Provera):
- Stopped early when CEE+MPA showed increased breast cancer, CHD, stroke, VTE
- Headline interpretation (2002): "HRT causes cancer and heart attacks" → 80% decline in prescriptions
- Reanalysis problems (now broadly accepted): 1. Wrong population: Mean age 63 — women 10-20+ years past menopause, when the arterial disease hypothesis is already established 2. Wrong hormones: Oral CEE (multiple estrogens from pregnant mare urine) + synthetic progestin MPA — neither is body-identical 3. Wrong endpoint: Used CEE+MPA for primary CVD prevention — guideline-endorsed use at the time, but no longer considered appropriate
The Timing Hypothesis (Window of Opportunity)
The consensus across 2024-2026 reviews: HRT effects are time-dependent.
| Timing of Initiation | Cardiovascular | Cognitive | VMS / Quality of Life | Recommendation |
|---|---|---|---|---|
| < 60 years old and/or < 10 years since menopause | Trend toward benefit; 32% reduction in CAD in meta-analysis of 23 trials (Korean MHT Guidelines 2025, J Menopausal Med 31(2):53, PMC12438153) | KEEPS-Cog and ELITE: no harm, no benefit on cognition in younger women | Strong benefit (PMID 12565178 family of reviews) | Initiate if symptomatic or per shared decision-making |
| > 60 years old and/or > 10 years past menopause | Increased CHD risk, especially in first years | WHIMS (women 65+) showed increased dementia risk (CEE+MPA arm) | Diminishing benefit; VMS often already resolved | Generally avoid initiation; continue if already on |
Swipe table →
- ELITE (Early vs Late Intervention Trial with Estradiol): Randomized 643 women to oral estradiol or placebo, stratified by <6 vs ≥10 years postmenopause. Reduced carotid intima-media thickness progression in early-initiation group (Hodis et al., NEJM 2016, PMID 26869218 surrogate benefit); no cognitive benefit in either group on extended follow-up.
- KEEPS (Kronos Early Estrogen Prevention Study): Low-dose oral CEE or transdermal estradiol + cyclical progesterone in recently menopausal women. No progression of CIMT or CAC. Mood/symptom benefit. No cognitive harm (KEEPS-Cog 4-year follow-up).
- ELITE + KEEPS confirm: Early-initiation hormone therapy is safe and possibly cardioprotective by surrogate markers; neither showed actual MACE reduction — that's the residual evidence gap.
Evidence source — peer-reviewed: - Manson JE et al., 2013 (JAMA 310:1353): WHI 13-year cumulative follow-up — net harm concentrated in older initiators - Rossouw JE et al., 2025 (JAMA Intern Med 185:1330): VMS subgroup — MHT did not elevate overall CVD in symptomatic women; CEE-alone showed more favorable CHD signals - Korean Society of Menopause 2025 Guidelines (J Menopausal Med 31(2):53, doi 10.6118/jmm.25103) - Bofill Rodriguez M et al., 2025 (Cochrane CD004143): Long-term HT for perimenopausal and postmenopausal women
FDA Label Changes (November 2025)
- FDA removed the boxed warning on systemic estrogen products (Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF, JAMA 2025, doi 10.1001/jama.2025.22259)
- FDA position: low-dose vaginal estrogen products are approved for genitourinary syndrome; boxed warning on those products was inappropriate
- The systemic estrogen boxed warning is being revised but not removed wholesale as of mid-2026; state of flux
- Scientific counter-response: Former WHI Data Safety Monitoring Board members published a JAMA Viewpoint (Feb 2026, JAMA 2844960) warning the FDA push "could put millions of women at risk" and demanding transparent advisory process
- PharmedOut STATNews op-ed (Jan 2026): Critics argue a "30-year itch" cycle of overpromising youth via hormones is repeating, citing telehealth-estrogen-clinic marketing
Honest synthesis: The 2025-2026 FDA changes are predominantly about removing inappropriate boxed warnings from low-dose vaginal estrogen and revising language on systemic products — not a wholesale "HRT is safe, everyone should take it" endorsement. The Cochrane 2025 and 2024-2025 Lancet / Lancet Healthy Longev reviews remain the authoritative evidence base, not marketing claims. Perimenopausal women with severe VMS, sleep disruption, and clear indications for systemic MHT should not be denied on the basis of 2002-era fear; older women initiating late should still be cautious.
Route of Administration — Why Transdermal Matters
| Route | VTE Risk vs Non-Use | Stroke Risk | Notes |
|---|---|---|---|
| Oral estrogen | RR ~2.5 (Scarabin 2003, PMID 12927428; Canonico 2008, PMID 18495631) | RR ~1.3-1.5 | First-pass hepatic effect on clotting factors |
| Transdermal estradiol (patch/gel) | RR ~1.0 (neutral) | Neutral to slight reduction | Bypasses first-pass; preferred for VTE risk, smokers, obesity, migraine |
| Combined oral contraceptives | RR 3-6 | ↑ | Same first-pass mechanism; not for postmenopausal women |
| Vaginal (low-dose estradiol, estriol) | Systemic absorption minimal at standard doses | Neutral | Effective for GSM only; not for VMS/bone |
Swipe table →
- Clinical implication: For women with any elevated VTE risk (BMI > 30, factor V Leiden, smoking, family history, prior clot, age > 60 at initiation), transdermal estradiol is the default. Per menopause society guidance (NAMS, IMS), transdermal is preferred in most cases regardless.
Type of Progestogen — MPA vs Micronized Progesterone
WHI's MPA arm showed increased breast cancer signal. Subsequent observational and mechanistic data suggest micronized progesterone (Prometrium) has a more favorable profile than synthetic progestins (MPA, norethindrone, levonorgestrel):
- E3N-EPIC cohort (Fournier et al., 2008, PMID 18463510): Micronized progesterone did not increase breast cancer risk over 8 years; synthetic progestins did
- Collaborative Group on Hormonal Factors (Lancet 2019, PMID 31474332): IPD meta-analysis of 58 studies — micronized progesterone + estrogen had lower breast cancer RR than synthetic progestin combinations
- Mechanism: MPA has glucocorticoid activity and known breast-epithelial mitogenic effects; micronized progesterone lacks these
Uses
The perimenopause question is harder than postmenopausal initiation because cycles are still happening (irregularly) and the indication is often symptom-driven, not prevention-driven:
| Issue | Approach |
|---|---|
| — | Low-dose combined oral contraceptive (still safe pre-50 in non-smokers) OR cyclical progesterone + transdermal estradiol in luteal phase |
| — | — |
| Mood lability, sleep disruption | Micronized progesterone HS often suffices (allopregnanolone metabolite → GABA-A) |
| GSM only | — |
| Heavy/irregular bleeding workup | Endometrial assessment first (transvaginal ultrasound ± biopsy) before starting — perimenopause is also a window of unopposed-estrogen endometrial hyperplasia risk |
| Bone protection for high-risk perimenopausal women | Standard MHT sufficient; otherwise treat per osteoporosis guidelines |
Swipe table →
Estrogen and Cognition — 2025 Update
The 2025 systematic review and meta-analysis (Lancet Healthy Longev 2025, doi 10.1016/j.lanhl.2025.100803) of MHT and MCI/dementia:
- Reviewed RCTs + prospective studies Jan 2000-Oct 2025
- Overall finding: MHT was not associated with risk of MCI or dementia when initiated in women aged 50-59
- Timing matters: Initiation in women ≥65 (WHIMS data) was associated with increased dementia risk — confirming the window-of-opportunity hypothesis
- ELITE 10-year cognitive follow-up (ref PLOS Medicine PMID: 10.1371/journal.pmed.1004435): No cognitive benefit or harm in younger women; no signal of harm in late-initiation either (smaller N than WHIMS)
- Bottom line: Initiating MHT for cognitive protection in recently menopausal women is not supported by current evidence; using MHT and getting cognition benefit is incidental to VMS/sleep relief, not a primary indication
Estrogen and Long-Term Mortality
- WHI 18-year cumulative follow-up (Manson et al., JAMA 2017 PMID 28898978): All-cause mortality was not significantly different between CEE+MPA, CEE-alone, and placebo groups
- The BMJ 2025 mortality review (BMJ 392:bmj-2025-085998): In symptomatic recently-menopausal women with proper selection, MHT-related mortality is not elevated vs never-use
- Breast cancer mortality in WHI: became statistically significant at 11 years of follow-up in the CEE+MPA arm (cumulative exposure)
Benefits of HRT (Modern Evidence-Synthesized)
- Vasomotor symptom relief: Strongest evidence; most efficacious treatment (PMID 12565178 family)
- Bone preservation / osteoporosis prevention: Strong; reduces hip fracture risk (WHI confirmed)
- Cardiovascular protection: Probable if initiated <60 / <10y from menopause; not for primary or secondary prevention of CVD
- Cognitive protection: Not supported by current evidence as primary indication; no harm in younger women
- Improved sleep, mood, QoL: Strong for VMS-related sleep/mood
- Genitourinary health: Low-dose vaginal estrogen highly effective with minimal systemic exposure
- Type 2 diabetes reduction: WHI showed ~21% reduction in new diabetes — mechanism unclear, not an indication
Cancer Risk — Honest Summary
| Outcome | Effect | Notes |
|---|---|---|
| Breast cancer (CEE+MPA) | RR ~1.24 cumulative over 5+ years; persists post-stop; mortality signal at 11y | Synthetic progestin driver; micronized progesterone lower |
| Breast cancer (CEE alone, post-hysterectomy) | Neutral or slight reduction (WHI CEE-alone arm) | Estrogen-alone in women without uterus is favorable on this endpoint |
| Endometrial cancer | Increased with unopposed estrogen (well-established) | Must combine with progestin or progesterone in women with intact uterus |
| Ovarian cancer | RR ~1.2-1.4 with >5y use; absolute risk very low | Monitor symptoms; not a contraindication |
| Colorectal cancer | Reduced in WHI CEE+MPA arm (RR ~0.6) | Serendipitous; mechanism unclear |
| Lung cancer | Neutral overall; mortality may be slightly increased in smokers (WHI subgroup) | Caution in current/past heavy smokers |
Swipe table →
Monitoring on HRT
- Baseline: Lipid panel, fasting glucose/HbA1c, TSH, vitamin D, FSH/estradiol (if perimenopausal), mammogram (within 1 year), endometrial assessment if perimenopausal with abnormal bleeding
- 3-month follow-up: Symptom response, BP, weight, side effects
- Annually: Mammogram, lipid panel, breast self-awareness; re-evaluate indication
- Bone density (DEXA): Baseline at 65 or per risk; HRT provides protection but reassess periodically
- Continuous reassessment: Reassess indication, route, dose, and duration annually. Many guidelines (NAMS 2022, IMS 2016) recommend no arbitrary stop date if tolerating well and indication persists
05Thyroid Optimization
The Undertreated Epidemic
- Conventional medicine treats only overt hypothyroidism (TSH > 4.5-10)
- Subclinical hypothyroidism (TSH 2.5-4.5 with symptoms) affects 5-15% of adults
- Many symptomatic patients are told their thyroid is "normal"
- Optimal ranges: TSH 0.5-2.0, free T3 in upper third of range, free T4 mid-to-upper range
Treatment Considerations
- Levothyroxine (T4) alone: Standard treatment — but many don't convert T4→T3 efficiently
- Combination T4/T3 (desiccated thyroid or liothyronine): Better for some patients
- Reverse T3: Elevated rT3 indicates poor conversion; may benefit from T3-containing therapy
- Thyroid peptides: Epitalon and thyroid bioregulators from Khavinson research
06DHEA and Pregnenolone
DHEA
- Most abundant circulating steroid hormone; declines ~10% per decade
- Benefits (evidence): Improved mood, libido, bone density, skin health in older adults
- Monitoring: DHEA-S levels, hormone panel
Pregnenolone
- "Mother hormone" — precursor to all steroid hormones
- Neurosteroid with direct effects on cognition and mood
- Role: Can support downstream hormone production without directly suppressing any pathway
07Critical Analysis
What Conventional Medicine Gets Wrong
- "Normal" ranges are too broad — symptomatic patients are dismissed
- Fear of hormones is disproportionate to evidence — especially for TRT and HRT
- Only treats deficiency, not optimization — preventive hormone support is discouraged
- Ignores hormone interactions — treating one hormone without considering the cascade
- Pharmaceutical bias — drugs for symptoms (antidepressants, statins) preferred over hormonal root causes
- Perimenopause is the missing chapter — most "menopause" guidance is post-menopause; the transition itself is poorly managed
Risks and Honest Assessment
- TRT and cardiovascular risk: The data is genuinely mixed. Proper monitoring and physiologic dosing minimize risk.
- HRT and breast cancer: The WHI showed increased risk with combined estrogen + synthetic progestin. Bioidentical micronized progesterone appears to have lower risk. Duration matters. CEE-alone (in women without uterus) was neutral or slightly protective.
- HRT and dementia: Increased risk only when initiated in women ≥65 (WHIMS data); not supported as primary indication in younger women.
- Cancer risk with any hormone therapy: Regular screening is essential. Active cancer is a contraindication.
- Suppression of endogenous production: All exogenous hormones suppress natural production to some degree.
Red Flags and Cautionary Signals
- Influencer-driven hormone clinics: "Bioidentical hormone optimization" clinics selling compounded BHT (custom-mixed) lack FDA oversight for sterility, potency, and consistency. FDA-approved 17β-estradiol and micronized progesterone exist and are usually covered by insurance.
- Without periodic re-evaluation: "Stay on it forever" framing is marketing, not evidence. Annual reassessment is the standard of care.
- No labs before starting: Skipping baseline FSH/estradiol/lipids/mammogram/eligible endometrial assessment is below the standard of care.
- Marketing over evidence: "Anti-aging" framing of HRT obscures that the indications are symptom-driven (VMS, GSM, osteoporosis prevention in high-risk women). It is not a general longevity intervention with proven life-extension benefit.
08Connections
09Sources
- PubMed 39248210PubMed 39248210
- PubMed 40720963PubMed 40720963
- PMC12438153PMC12438153
- PubMed 12565178PubMed 12565178
- PubMed 26869218PubMed 26869218
- DOI 10.6118/jmm.25103DOI 10.6118/jmm.25103
- DOI 10.1001/jama.2025.22259DOI 10.1001/jama.2025.22259
- PubMed 12927428PubMed 12927428
- PubMed 18495631PubMed 18495631
- PubMed 18463510PubMed 18463510
- PubMed 31474332PubMed 31474332
- DOI 10.1016/j.lanhl.2025.100803DOI 10.1016/j.lanhl.2025.100803
- PubMed 28898978PubMed 28898978
- PubMed 24036221PubMed 24036221
- DOI 10.1001/jamainternmed.2025.4510DOI 10.1001/jamainternmed.2025.4510
- PubMed 27009212PubMed 27009212
- PubMed 26544651PubMed 26544651
- DOI 10.1371/journal.pmed.1004435DOI 10.1371/journal.pmed.1004435
10Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.